{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T04:38:03Z","timestamp":1727239083134},"reference-count":24,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/17425255.2023.2292736","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T08:51:55Z","timestamp":1701939115000},"page":"881-888","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic evaluation of sofosbuvir\/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older"],"prefix":"10.1080","volume":"19","author":[{"given":"Jessica","family":"Tuan","sequence":"first","affiliation":[{"name":"Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, New Haven, CT, USA"},{"name":"Yale AIDS Program, 135 College St, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adaora","family":"Okoli","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onyema","family":"Ogbuagu","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, New Haven, CT, USA"},{"name":"Yale AIDS Program, 135 College St, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1028"},{"key":"e_1_3_4_4_1","unstructured":"Hepatitis C. World Health Organization. Jun 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"key":"e_1_3_4_5_1","unstructured":"Prescribing Information for Epclusa. Gilead. 2022. https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/epclusa\/epclusa_pi.pdf"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17237"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i12.1117"},{"key":"e_1_3_4_8_1","unstructured":"HCV guidance: recommendations for testing managing and treating hepatitis C. AASLD\/IDSA. Oct 2022. https:\/\/www.hcvguidelines.org\/sites\/default\/files\/full-guidance-pdf\/AASLD-IDSA_HCVGuidance_October_24_2022.pdf"},{"key":"e_1_3_4_10_1","unstructured":"Summary on compassionate use for Ledipasvir\/Sofosbuvir. European Medicines Agency 2014. https:\/\/www.ema.europa.eu\/en\/documents\/other\/summary-compassionate-use-ledipasvir\/sofosbuvir_en.pdf"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00774-0"},{"key":"e_1_3_4_12_1","article-title":"Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-Infected adult subjects","author":"Kirby B","year":"2013","unstructured":"Kirby B, Gordi T, Symonds W, et al. Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-Infected adult subjects. AASLD. 2013. https:\/\/www.natap.org\/2013\/AASLD\/AASLD_69.htm","journal-title":"AASLD"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15175"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix260"},{"key":"e_1_3_4_17_1","unstructured":"Sofosbuvir-Velpatasvir. Hepatitis C online. 2023. https:\/\/www.hepatitisc.uw.edu\/page\/treatment\/drugs\/epclusa\/prescribing-information#S14.8"},{"key":"e_1_3_4_18_1","unstructured":"U.S. FDA Approves Expanded Labeling For Epclusa (Sofosbuvir\/Velpatasvir) For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV. Gilead 1 Aug 2017.https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2017\/8\/us-fda-approves-expanded-labeling-for-epclusa-sofosbuvirvelpatasvir-for-the-treatment-of-chronic-hepatitis-c-in-patients-coinfected-with-hiv"},{"key":"e_1_3_4_19_1","unstructured":"U.S. Food and drug administration approves New formulation of epclusa expanding pediatric indication to treat children ages 3 and older with chronic hepatitis C. Gilead 10 Jun 2021. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2021\/6\/us-food-and-drug-administration-approves-new-formulation-of-epclusa-expanding-pediatric-indication-to-treat-children-ages-3-and-older-with-chronic"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.08.088"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.03.047"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11397.1"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002449"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac715"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1264"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy201"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2023.2292736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T22:08:32Z","timestamp":1727215712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2023.2292736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/17425255.2023.2292736"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2023.2292736","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"type":"print","value":"1742-5255"},{"type":"electronic","value":"1744-7607"}],"subject":[],"published":{"date-parts":[[2023,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}